Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

Waks, A. G.; Cohen, O.; Kochupurakkal, B.; Kim, D.; Dunn, C. E.; Buendia Buendia, J.; Wander, S.; Helvie, K.; Lloyd, M. R.; Marini, L.; Hughes, M. E.; Freeman, S. S.; Ivy, S. P.; Geradts, J.; Isakoff, S.; LoRusso, P.; Adalsteinsson, V. A.; Tolaney, S. M.; Matulonis, U.; Krop, I. E.; D’Andrea, A. D.; Winer, E. P.; Lin, N. U.; Shapiro, G. I.; Wagle, N.

Published in

Elsevier, Annals of Oncology, 5(31), p. 590-598, 2020

DOI: 10.1016/j.annonc.2020.02.008

Tools

Export citation

Search in Google Scholar

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

Journal article published in 2020 by A. G. Waks, O. Cohen, B. Kochupurakkal, D. Kim, C. E. Dunn, J. Buendia Buendia, S. Wander, K. Helvie, M. R. Lloyd

, L. Marini, M. E. Hughes, S. S. Freeman

, S. P. Ivy, J. Geradts, S. Isakoff and other authors.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer